By Dr Andrew On Wah Yam

Other

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Data from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.c.8387594

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Figure 1 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872536

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Figure 2 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872533

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Figure 3 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872530

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Figure 4 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872527

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Figure 1 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872524

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Figure 2 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872521

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Figure 3 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872518

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Figure 4 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872515

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Figure 5 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872512

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Figure 6 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872509

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Table 1 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872506

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Supplementary Table 2 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872503

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Table 1 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872500

Talmor B; Marastoni S; Lau B; Yam AO; Yeung N; Lin H-M; Li ZJ; Woo H; Pranavan G; Stricker PD; Horvath LG; Koritzinsky M; Wouters BG; Crumbaker M; Joshua AM, 2026, Table 2 from A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results, http://dx.doi.org/10.1158/2767-9764.31872497

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2025, Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.30699957

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2025, Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.30699951

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2025, Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.30699948

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2025, Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.30699945

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2025, Supplementary Data from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.30699942

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2025, Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.30699939

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 1 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027266.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 1 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027266

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 2 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027263

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 2 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027263.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 3 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027260

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 3 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027260.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 4 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027257

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 4 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027257.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Supplementary Data from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027254

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Supplementary Data from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027254.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Supplementary Table 1 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027251

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Supplementary Table 1 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027251.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Data from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.c.6599657.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Data from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.c.6599657

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633202

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633202.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633199.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633199

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633196.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633196

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633193.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633193

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Supplementary Data from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633187.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Supplementary Data from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633187

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633184

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633184.v1

Back to profile page